Hearing loss in Turner syndrome

Morimoto, Noriko; Tanaka, Toshiaki; Taiji, Hidenobu; Horikawa, Reiko; Naiki, Yasuhiro; Morimoto, Yuji; Kawashiro, Nobuko

doi:10.1016/j.jpeds.2006.06.071

Cited by 50 publications

(50 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The prevalence of recurrent otitis media in this study (68% of the patients) is in agreement with most TS studies (Anderson et al, 1969;Barrenas et al, 1999;Dhooge et al, 2005;Gungor et al, 2000;Hultcrantz et al, 1994;Hultcrantz, 2003;Hultcrantz and Sylven, 1997;Morimoto et al, 2006;Stenberg et al, 1998). In literature, a history of recurrent middle ear infections is described in 19.6e91% of patients (Anderson et al, 1969;Barrenas et al, 1999;Dhooge et al, 2005;Gawron et al, 2008;Gungor et al, 2000;Hultcrantz et al, 1994;Hultcrantz, 2003;Hultcrantz and Sylven, 1997;Morimoto et al, 2006;Parkin and Walker, 2009;Sculerati et al, 1990Sculerati et al, , 1996Stenberg et al, 1998;Watkin, 1989).…”

Section: Middle Ear Disease and Otomicroscopic Anomaliessupporting

confidence: 90%

Ear and hearing problems in relation to karyotype in children with Turner syndrome

et al. 2011

View full text Add to dashboard Cite

Section: Middle Ear Disease and Otomicroscopic Anomaliessupporting

confidence: 90%

Ear and hearing problems in relation to karyotype in children with Turner syndrome

et al. 2011

View full text Add to dashboard Cite

“…The hearing thresholds at high frequencies were correlated with age (more apparent in 45,X) and height (95).…”

Section: Ent Problemsmentioning

confidence: 95%

“…By contrast, screening for celiac disease by measuring tissue tTg IgA antibodies was the least common test (119). (93,95). In younger patients, CHL was more common (94).…”

Section: Autoimmune Diseases During Transitionmentioning

confidence: 99%

TRANSITION IN ENDOCRINOLOGY: Treatment of Turner's syndrome during transition

Gawlik

Małecka-Tendera

2014

European Journal of Endocrinology

View full text Add to dashboard Cite

Transition in health care for young patients with Turner's syndrome (TS) should be perceived as a staged but uninterrupted process starting in adolescence and moving into adulthood. As a condition associated with high risk of short stature, cardiovascular diseases, ovarian failure, hearing loss and hypothyroidism, TS requires the attention of a multidisciplinary team. In this review paper, we systematically searched the relevant literature from the last decade to discuss the array of problems faced by TS patients and to outline their optimal management during the time of transfer to adult service. The literature search identified 233 potentially relevant articles of which 114 were analysed. The analysis confirmed that all medical problems present during childhood should also be followed in adult life. Additionally, screening for hypertension, diabetes mellitus, dyslipidaemia, and osteoporosis is needed. After discharge from the paediatric clinic, there is still a long way to go.

show abstract

“…Although many studies have reported data on otologic abnormalities in patients with TS [5,6,7,8,9,10,13,24], none has evaluated ear disease in a large cohort of very young GH-treated vs. untreated girls in a prospective, longitudinal fashion. Thus, the age at onset of ear and hearing problems in TS, and their natural history, have been largely unknown.…”

Section: Discussionmentioning

confidence: 99%

“…In addition to high rates of CHL, a high prevalence of SNHL has been reported in older girls and women with TS [7,8,10,24,31,32]. The prevalence of SNHL increases with age; almost 50% of the patients in a Canadian study had evidence of SNHL by 21 years of age [33]and >1 in 4 women with TS require hearing aids [32].…”

Section: Discussionmentioning

confidence: 99%

Growth Hormone Treatment Does Not Affect Incidences of Middle Ear Disease or Hearing Loss in Infants and Toddlers with Turner Syndrome

Davenport¹,

Roush

Liu

et al. 2010

Horm Res Paediatr

View full text Add to dashboard Cite

Context: No randomized, controlled, prospective study has evaluated the effect of growth hormone (GH) on the rates of middle ear (ME) disease and hearing loss in girls with Turner syndrome (TS). Design: A 2-year, prospective, randomized, controlled, open-label, multicenter, clinical trial (‘Toddler Turner Study’; August 1999 to August 2003) was carried out. Setting: The study was conducted at 11 US pediatric endocrine centers. Subjects: Eighty-eight girls with TS, aged 9 months to 4 years, were enrolled. Intervention: The interventions comprised recombinant GH (50 µg/kg/day, n = 45) or no treatment (n = 43) for 2 years. Main Outcome Measures: The outcome measures included occurrence rates of ear-related problems, otitis media (OM) and associated antibiotic treatments, tympanometric assessment of ME function and hearing assessment by audiology. Results: At baseline, 57% of the girls (mean age = 1.98 ± 1.00 years) had a history of recurrent OM, 33% had undergone tympanostomy tube (t-tube) insertion and 27% had abnormal hearing. There was no significant difference between the treatment groups for annual incidence of OM episodes (untreated control: 1.9 ± 1.4; GH-treated: 1.5 ± 1.6, p = 0.17). A quarter of the subjects underwent ear surgeries (mainly t-tube insertions) during the study. Recurrent or persistent abnormality of ME function on tympanometry was present in 28–45% of the girls without t-tubes at the 6 postbaseline visits. Hearing deficits were found in 19–32% of the girls at the annual postbaseline visits. Most of these were conductive deficits, however, 2 girls had findings consistent with sensorineural hearing loss, which was evident before 3 years of age. Conclusions: Ear and hearing problems are common in infants and toddlers with TS and are not significantly influenced by GH treatment. Girls with TS need early, regular and thorough ME monitoring by their primary care provider and/or otolaryngologist, and at least annual hearing evaluations by a pediatric audiologist.

show abstract

Hearing loss in Turner syndrome

Cited by 50 publications

References 29 publications

Ear and hearing problems in relation to karyotype in children with Turner syndrome

Ear and hearing problems in relation to karyotype in children with Turner syndrome

TRANSITION IN ENDOCRINOLOGY: Treatment of Turner's syndrome during transition

Growth Hormone Treatment Does Not Affect Incidences of Middle Ear Disease or Hearing Loss in Infants and Toddlers with Turner Syndrome

Contact Info

Product

Resources

About